Engineering mRNA-Lipid nanoparticle (LNP) vaccines against multidrug resistant bacteria: current and future prospects

This review highlights the significant potential of mRNA-lipid nanoparticle (LNP) technology for application in bacterial vaccines, with a long-term goal to provide critical tools in controlling problematic microbial infections regardless of their antimicrobial resistance (AMR) profile. The current landscape of bacterial vaccine development, including methods for identification of candidate antigens, are discussed along with emerging design principles for LNP delivery systems. We focus on mRNA-LNP systems for delivery of bacterial vaccine antigens in large part due to their extensive clinical validation, compatibility with reverse vaccinology, and growing prominence in modern vaccinology. Attention is also given to emerging opportunities to develop effective tools to combat severe infections, particularly those caused by AMR bacterial infections. Specific advantages and challenges of RNA-based vaccine platforms and LNP delivery systems compared to other vaccine modalities including strategies are highlighted, with a focus on particular strengths in conserved antigen identification via genome sequencing and recent advances in optimizing LNP composition for induction of strongly protective immunity for vaccine delivery. We argue that mRNA-LNP technology combined with reverse vaccinology approaches has the potential to improve and accelerate bacterial vaccine development, particularly for broadly protective immunity less dependent on bacterial strain surface composition and which are entirely dependent on host immunity, making them agnostic to the issue of antimicrobial resistance.

Authors

Institutions

Publication Details

Journal
FEMS Microbiology Reviews
Published
2026-11-13
DOI
https://doi.org/10.1093/femsre/fuag059
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Engineering mRNA-Lipid nanoparticle (LNP) vaccines against multidrug resistant bacteria: current and future prospects

Inés Bleriot, Cedric A. Brimacombe, Ehsan Ansari Dezfouli, Pieter R. Cullis et al.
6 links
FEMS Microbiology Reviews
RNA Interference and Gene Delivery
article

Engineering mRNA-Lipid nanoparticle (LNP) vaccines against multidrug resistant bacteria: current and future prospects

Inés Bleriot, Cedric A. Brimacombe, Ehsan Ansari Dezfouli, Pieter R. Cullis, Muhammad Muzamil Khan, James A Russell
article en

Abstract

This review highlights the significant potential of mRNA-lipid nanoparticle (LNP) technology for application in bacterial vaccines, with a long-term goal to provide critical tools in controlling problematic microbial infections regardless of their antimicrobial resistance (AMR) profile. The current landscape of bacterial vaccine development, including methods for identification of candidate antigens, are discussed along with emerging design principles for LNP delivery systems. We focus on mRNA-LNP systems for delivery of bacterial vaccine antigens in large part due to their extensive clinical validation, compatibility with reverse vaccinology, and growing prominence in modern vaccinology. Attention is also given to emerging opportunities to develop effective tools to combat severe infections, particularly those caused by AMR bacterial infections. Specific advantages and challenges of RNA-based vaccine platforms and LNP delivery systems compared to other vaccine modalities including strategies are highlighted, with a focus on particular strengths in conserved antigen identification via genome sequencing and recent advances in optimizing LNP composition for induction of strongly protective immunity for vaccine delivery. We argue that mRNA-LNP technology combined with reverse vaccinology approaches has the potential to improve and accelerate bacterial vaccine development, particularly for broadly protective immunity less dependent on bacterial strain surface composition and which are entirely dependent on host immunity, making them agnostic to the issue of antimicrobial resistance.

FEMS Microbiology Reviews
University of British Columbia (CA), St. Paul's Hospital (CA), Centre for Heart Lung Innovation (CA)
Good health and well-being
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon